CLINICAL_TRIALS
trial_result
· 2018-06-25
Clinical Trial Update: A Validation and Dosimetry Study of GSK2634673F PET Ligand [Phase 1]
Summary
Phase 1 study evaluating the GSK2634673F PET ligand for validation and dosimetry in idiopathic pulmonary fibrosis has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: TERMINATED